Latest News
Topic
All
Corporate news
Partners
Awards
Thermal
AI
ColorVu
Events
Alarm
ESG
PanoVu
Access control
Traffic management
Solution
Perimeter protection
LED
Temperature screening
MinMoe
Software
Deepinview cameras
8K
DVR
Solar-powered security
Audio
Interactive Flat Panel
Sustainability
Explosion or corrosion resistant cameras
Video intercom
Video intercom
Networking
NVR 5.0
Turbo HD 8.0
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Search news
Cancel
Topic
All
Corporate news
Partners
Awards
Thermal
AI
ColorVu
Events
Alarm
ESG
PanoVu
Access control
Traffic management
Solution
Perimeter protection
LED
Temperature screening
MinMoe
Software
Deepinview cameras
8K
DVR
Solar-powered security
Audio
Interactive Flat Panel
Sustainability
Explosion or corrosion resistant cameras
Video intercom
Video intercom
Networking
NVR 5.0
Turbo HD 8.0
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Reset
Submit

Hikvision’s new business team to develop intelligent solutions for fentanyl-related substances regulation

Hikvision, the world’s leading supplier of innovative video security products and solutions, has announced a new business team dedicated towards developing intelligent solutions for fentanyl-related substances regulation. This is a solid move to respond and contribute to the joint efforts between the governments of China and the U.S., together with the international community, to combat drug crimes and protect the public health and safety. Relying on Hikvision’s advanced video technology and big data analytics, the new dedicated team will be committed to develop intelligent solutions for fentanyl regulation.

 

In recent years, how to effectively regulate and control the new types of psychoactive substances, including fentanyl, has become a serious international problem. In late 2018, the leaders and governments of China and the U.S. reached an agreement on cooperation in law enforcement and Fentanyl control. Recently, China’s Ministry of Public Security, National Health Commission, and National Medical Products Administration jointly announced to regulate all fentanyl-related substances as a class of controlled substances (with non-medical use), which takes effective May 1, 2019.

 

Due to its numerous variants and low threshold for synthesis, Fentanyl has put forward a new challenge to the technology of drug inspection and control. The new dedicated team of Hikvision is composed of experts in many fields like system architecture, central platform, algorithms and products. With experience in intelligent video applications and big data analytics, the team will conduct in-depth research on key technical issues existing in production, storage and transportation of Fentanyl, and develop customized intelligent solutions for optimization of drug control.

 

Mr. Cai Changyang, Senior VP of Hikvision, said: "Creating more value to the society through our advanced technology has always been the goal Hikvision pursued. The problem of new types of drugs, including fentanyl-related substances has caused risks and hazards worldwide. Therefore, the company has decided to set up the dedicated team to respond to the challenges and to join the joint endeavor, aiming to make contributions to protect the physical and mental health of people, as well as safeguard our communities and society. "

 

 

Newsroom

Explore the latest news, customer stories, and industry insights from Hikvision

Hikvision.com uses strictly necessary cookies and related technologies to enable the website to function. With your consent, we would also like to use cookies to observe and analyse traffic levels and other metrics / show you targeted advertising / show you advertising on the basis of your location / tailor our website's content. For more information on cookie practices please refer to our cookie policy.

 

Contact Us
Hik-Partner Pro close
Hik-Partner Pro
Security Business Assistant. At Your Fingertips. Learn more
Hik-Partner Pro
Scan and download the app
Hik-Partner Pro
Hik-Partner Pro

Get a better browsing experience

You are using a web browser we don’t support. Please try one of the following options to have a better experience of our web content.